NYSE AIZ |: 98.31 ?(+0.52)
Menu

Statutory Statements

The following statutory financial information of Assurant has been determined in conformity with statutory accounting practices ("SAP") prescribed or permitted by the Insurance Departments of the applicable state. SAP does not prescribe or permit consolidation. The results for past accounting periods are not necessarily indicative of results to be expected for any future accounting period. The Statutory Financial Statements were prepared in conformity with SAP, which principles differ in certain significant respects from accounting principles generally accepted in the United States of America ("GAAP").

Below are ten of the largest legal entities that represent the majority of Assurant's total statutory income. The attached files are fairly large in size, which may cause a delay in downloading the information.

The combined statutory net income, excluding intercompany dividends and surplus note interest, and capital and surplus of the Company’s U.S. domiciled statutory insurance subsidiaries follow:


Years Ended December 31,

2016
2015
2014
Statutory net income (loss)  
 
 
P&C companies  
$288,475
 
$437,422
 
$440,930
Life and Health companies  
600,240
 
(266,559)
 
67,270
Total statutory net income (1)   $888,715   $170,863   $508,200

December 31,

2016
2015
Statutory capital and surplus

 
P&C companies  
$1,175,565

$1,137,978
Life and Health companies  
508,928

1,153,137
Total statutory capital and surplus  

1,684,493


$2,291,115

(1)2015 includes higher loss experience and adverse claims development on 2015 individual major medical policies, a reduction in the 2014 estimated recoveries from the Affordable Care Act risk mitigation programs and $106,389 (after-tax) of exit and disposal costs, including premium deficiency reserves, severance and retention costs, long-lived asset impairments and similar exit and disposal costs related to the decision to exit the health business mentioned above.

The Company also has non-insurance subsidiaries and foreign insurance subsidiaries that are not subject to SAP. The statutory net income and statutory capital and surplus amounts presented above do not include foreign insurance subsidiaries in accordance with SAP.

Insurance enterprises are required by state insurance departments to adhere to minimum risk-based capital (“RBC”) requirements developed by the NAIC. All of the Company’s insurance subsidiaries exceed minimum RBC requirements.

The payment of dividends to the Company by any of the Company’s regulated U.S domiciled insurance subsidiaries in excess of a certain amount (i.e., extraordinary dividends) must be approved by the subsidiary’s domiciliary state department of insurance. Ordinary dividends, for which no regulatory approval is generally required, are limited to amounts determined by a formula, which varies by state. The formula for the majority of the states in which the Company’s subsidiaries are domiciled is based on the prior year’s statutory net income or 10% of the statutory surplus as of the end of the prior year. Some states limit ordinary dividends to the greater of these two amounts, others limit them to the lesser of these two amounts and some states exclude prior year realized capital gains from prior year net income in determining ordinary dividend capacity. Some states have an additional stipulation that dividends may only be paid out of earned surplus. If insurance regulators determine that payment of an ordinary dividend or any other payments by the Company’s insurance subsidiaries to the Company (such as payments under a tax sharing agreement or payments for employee or other services) would be adverse to policyholders or creditors, the regulators may block such payments that would otherwise be permitted without prior approval. Based on the dividend restrictions under applicable laws and regulations, the maximum amount of dividends that the Company’s U.S domiciled insurance subsidiaries could pay to the Company in 2017 without regulatory approval is approximately $319,000. No assurance can be given that there will not be further regulatory actions restricting the ability of the Company’s insurance subsidiaries to pay dividends.